Amylx Pharmaceuticals Inc vs Duke Energy Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Duke Energy Corp trades at $122.8 (market cap $96.05B). The key difference: Duke Energy Corp is far larger — about 36.4× Amylx Pharmaceuticals Inc's market cap, and Duke Energy Corp pays a 3.52% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DUK | |
|---|---|---|
Market Cap | $2.64B | $96.05B |
Sector | Health | Utilities |
52-Week High | $24.19 | $133.46 |
52-Week Low | $7.82 | $113.99 |
Enterprise Value | $2.39B | $188.56B |
Dividend Yield | — | 3.52% |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →